NCT05675410 2026-04-13
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
Children's Oncology Group
Emory University
C17 Council
Medical University of Vienna
University of Birmingham
Memorial Sloan Kettering Cancer Center
Columbia University